+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Candidemia Drug"

Candidemia - Pipeline Insight, 2024 - Product Thumbnail Image

Candidemia - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 40 Pages
  • Global
From
From
Candidemia - Epidemiology Forecast to 2032 - Product Thumbnail Image

Candidemia - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
  • 3 Results (Page 1 of 1)
Loading Indicator

Candidemia is a type of fungal infection caused by the yeast Candida. It is a serious infection that can affect the bloodstream, heart, lungs, and other organs. Treatment for candidemia typically involves antifungal medications, such as fluconazole, voriconazole, and amphotericin B. These drugs are used to treat a variety of other fungal infections, as well as other infectious diseases. The Candidemia Drug market is a subset of the larger Infectious Diseases Drugs market. It is composed of antifungal medications used to treat candidemia and other fungal infections. These drugs are used to treat a wide range of fungal infections, including those caused by Candida species, Aspergillus species, and Cryptococcus species. The Candidemia Drug market is highly competitive, with many companies offering a variety of antifungal medications. Some of the major players in the market include Pfizer, Merck, GlaxoSmithKline, AstraZeneca, Novartis, Sanofi, and Johnson & Johnson. Show Less Read more